Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Hydroxychloroquine, Arbidol and COVID-19: The Jury is Still Out!

Author(s): Elizabeth Gamboa and Joseph Varon*

Volume 17, Issue 1, 2021

Published on: 30 September, 2021

Page: [2 - 2] Pages: 1

DOI: 10.2174/1573398X1701210504142249

« Previous Next »
[1]
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat Rev Rheum 2020; 16(3): 155-66.
[2]
Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postgrad Med J 2020; 96(1139): 550-5.
[3]
Cohen MS. Hydroxychloroquine for the prevention of covid-19: Searching for evidence. N Engl J Med 2020; 383(6): 585-6.
[4]
Saag MS. Misguided use of hydroxychloroquine for COVID-19: The infusion of politics into science. JAMA 2020; 324(21): 2161-2.
[5]
Boriskin YS, Leneva IA, Pecheur EI, et al. Arbidol: A broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008; 15(10): 997-1005.
[6]
Chen W, Yao M, Fang Z, et al. A study on clinical effect of arbidol combined with adjuvant therapy on COVID-19. J Med Virol 2020; 92(11): 2702-8.
[7]
Khodashahi R, Naderi H, Bojdy A, et al. Comparison the effect of arbidol plus hydroxychloroquine vs hydroxychloroquine alone in treatment of COVID-19 disease: A randomized clinical trial. Curr Respir Med Rev 2020; 16(4): 252-62.
[8]
Funck-Brentano C, Nguyen LS, Salem JE. Retraction and republication: Cardiac toxicity of hydroxychloroquine in COVID-19. In: Lancet. 2020; 396: pp. (10245)e2-3.

Rights & Permissions Print Cite
Article Metrics
14
© 2025 Bentham Science Publishers | Privacy Policy